1. Denmark Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Pharma Equity Group A/S

Pharma Equity Group A/S

PEG.CO
Pharma Equity Group A/SDK flagNASDAQ Copenhagen
0.07
DKK
+0.00
- -
88.87MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-93.59
-3
-0.13
-0.06
0.01
-0.32
-0.71
-1.03
0.1
-0.01
-0.02
-0.04
-0.02
-0.02
Free Cash Flow per Basic Share
-4.07
-2.43
-0.14
-0.01
-0.22
-0.07
-0.11
-0.31
-0.04
- -
-0.02
-0.02
-0.01
-0.02
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-70.42
49.41
4.37
5.02
3.85
3.26
3.3
1.08
0.77
0.05
0.95
0.11
0.1
0.12
Tangible Book Value per Share
-69.58
49.53
4.58
5.18
3.83
3.26
3.3
1.08
0.77
0.05
0.01
0.03
0.02
0.03
Basic Weighted Avg Shares
2
2
22
19
22
24
20
32
56
954
1,080
1,068
1,228
1,023
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-142
-6
-3
-1
- -
-8
-14
-33
5
-9
-24
-41
-25
-24
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
-162
-3
-7
97
85
76
74
-23
-14
46
33
41
29
41
LT Debt
150
- -
17
- -
- -
- -
- -
- -
7
- -
8
8
5
8
Total Equity
-105
98
100
97
85
78
67
34
43
46
25
33
25
33
Return on Invested Capital (%)
- -
- -
- -
- -
-2.1
- -
- -
- -
0.11
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
2.09
- -
- -
- -
11.45
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-2.88
-1.1
0.2
-9.45
-19.92
-64.82
14.03
-21.32
-4.56
-7.09
-20.68
-4.26

Capital Structure

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
ST Debt
25
32
3
LT Borrowings
19
20
8
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,023
1,023
1,228
Market Capitalization
303
238
194

Working Capital

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
Total Current Assets
62
65
49
Cash, Cash Equivalents & STI
1
4
4
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
32
41
9
Payables & Accruals
- -
- -
- -
ST Debt
25
32
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-9.17%
-1.14%
-22.07%
Free Cash Flow
328.42%
90.76%
-22.75%
Net Income, GAAP
-462.69%
-40.89%
-37.5%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.02
2024
-0.01
-0.01
-0.01
- -
-0.04
2025
- -
- -
- -
- -
-0.02

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Christian Henrik Tange
Full Time Employees
2
Sector
Healthcare
Industry
Biotechnology
Address
Slotsmarken 18, 2.th. Horsholm Denmark 2970
IPO Date
May 16, 2023
Website
pharmaequitygroup.com
Similar Companies
Bioasis Technologies Inc. (BTI.V)
Newron Pharmaceuticals S.p.A. (NWPHF)
Tempest Therapeutics, Inc. (TPST)
Dna Group (T.R.) Ltd (DNA.TA)
ImmuCell Corporation (ICCC)
Affimed N.V. (0HL9.L)
Business
Pharma Equity Group A/S (PEG.CO) is a Danish investment company focused on the development and commercialization of pharmaceutical and biotech assets. The company acquires, finances, and advances late-stage clinical products targeting unmet medical needs in areas such as oncology, neurology, and rare diseases; it provides strategic funding, regulatory support, and partnership opportunities to portfolio companies. Its core offerings include equity investments in innovative drug candidates, milestone-based financing models, and operational expertise for clinical trial execution and market entry. Headquartered in Copenhagen, Denmark, and founded in 2016, Pharma Equity Group operates primarily in Europe with expanding interests in North American markets. Recent developments include a strategic alliance with a leading Nordic biotech firm in Q4 2025 to co-develop an oncology pipeline asset, alongside a NOK 150 million funding round closed in September 2025 to support Phase III trials for its flagship neurology program.